about
Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumorsAPOMAB, a La-specific monoclonal antibody, detects the apoptotic tumor response to life-prolonging and DNA-damaging chemotherapy.Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancerSsb1 and Ssb2 cooperate to regulate mouse hematopoietic stem and progenitor cells by resolving replicative stress.Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancerRad51 supports triple negative breast cancer metastasis.SCF-FBXO31 E3 ligase targets DNA replication factor Cdt1 for proteolysis in the G2 phase of cell cycle to prevent re-replication.Essential developmental, genomic stability, and tumour suppressor functions of the mouse orthologue of hSSB1/NABP2.MEK5-ERK5 pathway associates with poor survival of breast cancer patients after systemic treatments.Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or LeukemiaQuinazolinone derivatives as inhibitors of homologous recombinase RAD51.The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the La-specific antibody APOMABĀ®.Long-range regulators of the lncRNA HOTAIR enhance its prognostic potential in breast cancer.RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy.Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes.Breast cancer stem cells: treatment resistance and therapeutic opportunities.Tocotrienol as a potential anticancer agent.Eph family co-expression patterns define unique clusters predictive of cancer phenotype.Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.Long Noncoding RNAs CUPID1 and CUPID2 Mediate Breast Cancer Risk at 11q13 by Modulating the Response to DNA Damage.'Omics Approaches in Breast Cancer Research and Clinical Practice.Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma.Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor.Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretomeMutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11.Nutlin-3a is a potential therapeutic for ewing sarcoma.Multifunctional core-shell magnetic cisplatin nanocarriers.A simplified suite of methods to evaluate chelator conjugation of antibodies: effects on hydrodynamic radius and biodistribution.In vivo targeting of dead tumor cells in a murine tumor model using a monoclonal antibody specific for the La autoantigen.Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines.MITF and BRN2 contribute to metastatic growth after dissemination of melanoma.Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme.Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer.G9a drives hypoxia-mediated gene repression for breast cancer cell survival and tumorigenesis.EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.Characterization of a novel breast cancer cell line derived from a metastatic bone lesion of a breast cancer patient.Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer.A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer
P50
Q28474893-D4CC9501-65A2-4CC7-9616-FF69B7F01C30Q33413085-9EAFF34B-03E1-4C8C-8E30-B81BB81F969DQ33555064-A3F65F05-A8E7-417B-82F9-9AA4A6D56791Q33640202-33496951-9318-47B7-A771-ADFA17147EB0Q33917578-B371BC11-01D4-40E3-82B0-16453FFEDE9AQ33917622-71E17AB0-F6F9-490A-8947-F6D60A76306EQ34073816-16F0C75B-2690-4095-AD91-640520AD8A05Q34585782-F872F478-58B6-483F-8584-5CAC7E2CE8F9Q35238973-57E18BCE-3189-4FA3-9BAB-7180AE35E8C6Q35602598-8B767114-F161-45EB-8DEB-09DD3276CFC4Q35666005-2C7CD230-7B33-484A-9C92-D3516CFA7EF9Q36382053-537D794F-C077-423C-BF1C-5254241F2222Q37438751-961D94DA-0705-4278-8CF8-6FF1892CFAD1Q37528915-F72BF9B9-FC07-4693-A135-8F762A6FA49CQ37644990-9D6867CC-DBE4-487D-A98B-AEEF270F84DBQ37785490-0A03F9CD-2EDC-4B79-A382-26681EAC1CB5Q37839530-636734F9-94F9-4CB5-BEA8-62934387BF66Q37957725-9F690F0B-4E92-4C8A-88B3-1E9CDBD4BF8DQ38269791-4ABBF947-5D15-4552-9D4F-AFCE5AB59398Q38385463-88B5D0D1-9AF0-4229-9676-2A0A4336EA50Q38640565-8D3CDF09-F245-4349-B478-65538BCA4646Q38811676-7441413D-2FC7-4AAD-BD51-2A8820117F83Q38994037-7BECFB10-64B8-4A94-9740-2F435C6285E9Q39169737-128ABAAD-CDB5-4442-B06D-4C26BA90D89CQ39421527-783D7868-5B3E-4918-884B-EE1B525C947EQ39460398-4A2C5E2A-5EE2-4EEA-A2CB-258843A8F461Q39628701-33AC86CC-0688-4AD2-AFAC-0D98EF91722DQ39760991-1578538E-DBBF-41BA-A09E-30C3A06B4760Q39855359-3A29D469-9F1F-491D-8616-CCBA3B44E94AQ40079394-CD0F26EB-97D8-4281-A710-E92BD4DB6D1EQ40546156-C09D877A-0C8C-445A-AC33-CFBD5A51C095Q41536617-BB1EFF56-7EAD-485F-8394-4BEA3ABDAD65Q42514809-12A87B5F-2AE3-4236-9F4F-64E0E2D35ADBQ45839375-6E301871-FD8A-4E55-AC6A-3FEC7CDAE2EBQ46103372-18188983-AB7E-476A-8AB9-91B4A6180EB9Q47217251-90F7EDD4-4C81-4D89-8BC1-BD292B461C48Q51283425-97CCB984-F5A2-46C1-9F05-53E290341FFAQ52691103-F6A2A9AB-AA9C-4A2B-82C0-228EAD9555E3Q55387708-9E65C2B5-7CE2-4AE9-92A0-9A8089CC7BC3Q57305942-835C59BD-90C6-48E9-B883-2EBF96A33019
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
Õ°Õ„ÕæÕ”Õ¦ÕøÕæÕøÕ²
@hy
name
Fares Al-Ejeh
@ast
Fares Al-Ejeh
@en
Fares Al-Ejeh
@es
Fares Al-Ejeh
@nl
Fares Al-Ejeh
@sl
type
label
Fares Al-Ejeh
@ast
Fares Al-Ejeh
@en
Fares Al-Ejeh
@es
Fares Al-Ejeh
@nl
Fares Al-Ejeh
@sl
prefLabel
Fares Al-Ejeh
@ast
Fares Al-Ejeh
@en
Fares Al-Ejeh
@es
Fares Al-Ejeh
@nl
Fares Al-Ejeh
@sl
P1053
M-7032-2016
P106
P1153
6504391249
P1960
mhAb3AgAAAAJ
P21
P31
P3829
P496
0000-0002-1553-0077
P569
2000-01-01T00:00:00Z